News
科思
Homepage
/
News
/
Company News
/
Bioresorbable Vascular Scaffold Thrombosis in a Consecutive Cohort of 550 Patients

Bioresorbable Vascular Scaffold Thrombosis in a Consecutive Cohort of 550 Patients

  • Categories:Company News
  • Author:
  • Origin:
  • Time of issue:2016-08-12 09:27
  • Views:

(Summary description) To determine the rate of bioreasorbable vascular scaffold (BVS) thrombosis in a large, real-world population. BACKGROUND: There is some concern about device thrombosis after percutaneous coronary intervention (PCI) using BVS. No data have been published for PCI using both BVS and metal stents.

Bioresorbable Vascular Scaffold Thrombosis in a Consecutive Cohort of 550 Patients

(Summary description) To determine the rate of bioreasorbable vascular scaffold (BVS) thrombosis in a large, real-world population. BACKGROUND: There is some concern about device thrombosis after percutaneous coronary intervention (PCI) using BVS. No data have been published for PCI using both BVS and metal stents.

  • Categories:Company News
  • Author:
  • Origin:
  • Time of issue:2016-08-12 09:27
  • Views:
Information

　　OBJECTIVE: To determine the rate of bioreasorbable vascular scaffold (BVS) thrombosis in a large, real-world population. BACKGROUND: There is some concern about device thrombosis after percutaneous coronary intervention (PCI) using BVS. No data have been published for PCI using both BVS and metal stents.

　　METHODS: A cohort of 550 consecutive patients who underwent PCI for stable chest pain or acute coronary syndromes with implantation of at least one BVS (Absorb, Abbott Vascular) was systematically followed up by telephone interview and review of medical charts. Data on devicethrombosis were retrospectively analyzed in relationship to clinical and angiographic characteristics.

　　RESULTS: Follow-up was achieved in 533 patients (97%, median follow-up 233 days). A total of 964 BVS were implanted in 645 vessels. In addition, 234 metal stents were implanted in 149 patients, including "hybrid intervention" with the combined use of BVS and stents in the same artery in 122 patients. Documented were 15 definite, 1 probable, and 8 possible cases of device thrombosis (rate of definite/probable devicethrombosis: 3.0%). Of these, 6 definite and 6 possible thromboses could be unambiguously attributed to BVS (1.1%), whereas a total of 11 definite, 1 probable, and 8 possible thromboses were potentially attributable to BVS (2.3%). Definite device thrombosis occurred in 7/122 patientswith "hybrid intervention" (5.7%).

　　CONCLUSIONS: In a large real-world cohort treated with BVS, the rate of scaffold thrombosis was higher than published for randomized trials. A high rate of thrombosis was observed after combined implantation of BVS and stents within one vessel.

Previous: Amet withdrew the application for clinical trial approval of "Fully degradable peripheral vascular drug-eluting stent system", and will resubmit after further improvement of the application materials
Next: None
Previous: Amet withdrew the application for clinical trial approval of "Fully degradable peripheral vascular drug-eluting stent system", and will resubmit after further improvement of the application materials
Next: None
PeriSorb® fully degradable peripheral vascular stent completes the first FIM trial enrollment
2021 12-25

PeriSorb® fully degradable peripheral vascular stent completes the first FIM trial enrollment

This is the world's first 3D printed fully degradable peripheral stent implanted in the human body, marking that my country's 3D printing fully degradable peripheral stent with completely independent intellectual property rights has taken the lead in entering the clinical trial stage, and it also marks that my country's 3D printing technology has advanced to the world's leading level. A big step.
See more information
查看详情
Beijing adds 1,150 municipal-level "specialized, special and new" small and medium-sized enterprises
2021 12-03

Beijing adds 1,150 municipal-level "specialized, special and new" small and medium-sized enterprises

On December 1, the Beijing Economic and Information Bureau announced the list of the second to seventh batch of "specialized, special and new" small and medium-sized enterprises in Beijing in 2021. The list includes 1,150 small and medium-sized enterprises including Labtech, Digital Video, Geling Shentong, Moji Fengyun Technology, etc.
See more information
查看详情
Beijing Amet was recognized as a "specialized, special and new" enterprise
2021 12-02

Beijing Amet was recognized as a "specialized, special and new" enterprise

On December 1, 2021, the Beijing Municipal Bureau of Economy and Information issued an announcement on the seventh batch of "specialized, refined, and new" small and medium-sized enterprises in 2021. The announcement announced that Beijing Amet Medical Equipment Co., Ltd. was recognized as a "specialized, refined and new" enterprise. This event marks that Amet, as an innovative enterprise, has reached a high level in terms of scientific research strength, technical level and influence, and has been recognized by the competent government departments.
See more information
查看详情

Company Information

Beijing Advanced Medical Technologies,Ltd.Inc.

Contact Us

Address: Building 11, Zhongguancun Medical Equipment Park, No. 26, Yongwang West Road, Daxing District, Beijing

Tel：010-6297-7955           E-Mail：amt@ametcorp.com